J
Johnson & Johnson
Research and development, manufacture and sale of a range of products in the healthcare field
About Johnson & Johnson
Johnson & Johnson (J&J) is a global healthcare company that operates in three main segments: pharmaceuticals, medical devices, and consumer health products. The company serves a wide range of clients, including individual consumers, healthcare professionals, and large healthcare institutions. J&J operates in the healthcare market, which is characterized by high demand for innovative medical solutions and products that improve patient outcomes.
The business model of Johnson & Johnson is diversified across its three segments. In the pharmaceuticals segment, J&J develops and markets prescription drugs that address various medical conditions, including cancer, immunology, and infectious diseases. The medical devices segment offers a broad range of products used in surgery, orthopedics, and vision care. The consumer health segment provides over-the-counter products, baby care, skin and hair care, wound care, and other personal health products.
Johnson & Johnson makes money by selling its products to consumers, healthcare providers, and institutions. Revenue is generated through direct sales, partnerships, and distribution agreements. The company invests heavily in research and development to innovate and bring new products to market, ensuring a steady pipeline of offerings that meet the evolving needs of its clients.
J&J is also known for its commitment to diversity, equity, and inclusion, creating a workplace where employees feel empowered to share their unique perspectives. The company offers various career opportunities, including internships, co-ops, and leadership development programs, making it an attractive employer for both new graduates and experienced professionals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1886
- Headquarters
- New Brunswick, United States
- Listing
- IPO 1978
- Employees
- 134,851
- Open positions
- 81
- Dealroom signal
- 90.6/100
- Industry
- Health
- Sector
- Health, Biotechnology, observatoire healthtech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
- Investment activity
- 100 companies, latest Aug 2026
- Capital deployed
- $3.2B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jan 1978 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Johnson & Johnson is 3.1M monthly website visits, up 55% over the last three months. Johnson & Johnson's team grew 30.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Delix TherapeuticsBedford, United StatesApplying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics
$275Mvaluation
Firefly BioSouth San Francisco, United StatesUnlocking new classes of payloads to maximize the potential of ADCs
$1Bvaluation
Sail BiomedicinesUnited StatesProgrammable RNA medicines for in vivo CAR-T therapies.
→
Atraverse MedicalChicago, United StatesAtraverse Medical develops left-heart access technology to simplify workflows and enhance patient outcomes
$118Mvaluation
Mestag TherapeuticsSaffron Walden, United KingdomDeveloping antibody therapeutics targeting fibroblast-immune interactions
$160Mvaluation
Halda TherapeuticsNew Haven, United StatesPrecision oncology therapies targeting cancer via RIPTAC™ chimera
$3Bvaluation
Cellular OriginsRoyston, United KingdomEnabling patient access to cell therapies for today and tomorrow
$160Mvaluation
OBarisSchlieren, SwitzerlandOur mission is to improve the life quality of patients depending on painful injectable drugs by offering them
→
OBarisZurich, SwitzerlandDeveloping OctoPatch®, a painless patch for patients using injectable drugs
→
Ruilongnuofu Medical TechnologyMinhang District, ChinaDeveloping MIS and digital surgery solutions
$600Mvaluation
SensoriDallas, United StatesAlcohol-free tonic with nootropics and adaptogens
$4Mvaluation
Intracellular TherapiesNew York City, United StatesTherapeutics for central nervous system disorders
$377Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors8 additional known investors
Aisling Capital
Apple Tree Partners
Ben Franklin Technology Partners of Southeastern Pennsylvania
InterWest Partners
NaviMed Capital
New Generation Industry Leaders | World Economic Forum
Project Liberty Digital Incubator- PPProspect Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Johnson & Johnson on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Johnson & Johnson’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







